ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer - Seite 2
Julie E. Lang, MD, FACS, Director, USC Breast Cancer Program, Associate Professor of Surgery, Norris Comprehensive Cancer Center, University of Southern California,
commented:
"Our study showed that we are able to use a Parsortix liquid biopsy of circulating tumor cells to perform in-depth characterization of potentially clinically actionable
treatment opportunities in metastatic breast cancer patients. We demonstrated that circulating tumor cells may serve as a surrogate for biopsies of macrometastases. Successful validation
of our approach in future clinical studies could revolutionize clinical management of metastatic breast cancer and advance the promise of personalized cancer therapies, ultimately positively
changing the outcome for patients with metastatic disease."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"USC's ground-breaking work with ANGLE's Parsortix system over the last two years has delivered convincing data
that a simple blood test may be able to provide all the clinical information traditionally provided by the invasive, expensive solid biopsy. This is great news for ANGLE as it gives a clear
guide to the importance of being able to harvest and analyse these cells from patient blood."
USC's poster for SABCS is available online at https://angleplc.com/library/publications/. Key points are summarised below.
The solid biopsies for comparison had to be sourced from numerous different secondary cancer sites including skin, lung, pleural effusion (fluid around the lung), pericardial effusion (fluid around the heart), breast, lymph node, brain, liver, ascites, cerebrospinal fluid (fluid found in the brain and spine) and bone tissue. Gathering this material is an invasive surgical procedure and many women are not well enough to undergo the procedure.
Good RNA expression was obtained from 19/21 of the Parsortix liquid biopsy samples, which is a level of performance that has not been seen previously. The RNA-Seq downstream process used is one of the "subsequent analyses" being evaluated in ANGLE's ANG-002 400 subject clinical study for FDA clearance.
Lesen Sie auch
The US National Cancer Institute has estimated that, as at 1 January 2017, more than 150,000 women in the United States were living with metastatic breast cancer and this number is rising. There is a similar level of incidence worldwide. If a regulatory cleared blood test were available all of these women would be candidates for such tests, repeated on a periodic basis during the course of their metastatic disease.